V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 210002501 | 210007227 | 1.6 | 60 | Adjuvant (A) | 2018-03-13 | 2018-03-27 | null | N | N | CAPECITABINE + DOCETAXEL | 100816955 |
| 210002628 | 210007229 | 1.57 | 70.9 | null | 2018-07-15 | 2018-07-30 | FEC 100 | N | null | FEC | 101416903 |
| 210002644 | 210007231 | 1.72 | 70 | Palliative (P) | null | 2019-06-07 | null | 02 | N | ATEZOLIZUMAB + NAB-PACLITAXEL | 101704040 |
| 210002751 | 210007232 | null | null | null | 2017-03-08 | 2017-03-18 | null | 02 | null | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 100755182 |
| 210002805 | 210007233 | 1.61 | 53 | null | 2016-12-30 | 2017-01-10 | Paclitaxel+Trastuzumab wkly Maint | N | null | PACLITAXEL + TRASTUZUMAB | 101615942 |
| 210002826 | 210007234 | null | 0 | null | 2018-12-03 | 2018-12-10 | FEC 60 or 75 | N | null | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 100004928 |
| 210002871 | 210007235 | null | null | null | 2019-02-21 | 2019-03-08 | EC | 02 | null | EC | 100917260 |
| 210002942 | 210007236 | null | 94 | null | 2018-02-19 | 2018-02-22 | FEC + DOCETAXEL | null | null | FEC + DOCETAXEL | 101053988 |
| 210002947 | 210007237 | 1.54 | 67 | null | 2017-02-22 | 2017-03-30 | FEC 60 or 75 | N | null | FEC | 101147575 |
| 210003226 | 210007239 | null | null | null | 2018-11-08 | 2018-11-18 | CARBOPLATIN | null | null | NIRAPARIB | 100456723 |
| 210003249 | 210007240 | 1.55 | 128 | Palliative (P) | null | 2018-11-13 | EC | null | N | EC | 100715933 |
| 210003283 | 210007242 | null | null | null | 2021-06-23 | 2021-06-23 | FEC | null | null | ALECTINIB | 101017890 |
| 210003324 | 210007243 | 1.58 | 63.6 | Palliative (P) | null | 2017-03-06 | Paclitaxel+Trastuzumab wkly Maint | N | N | CYCLOPHOSPHAMIDE + DOCETAXEL | 100837867 |
| 210003439 | 210007245 | 1.63 | 82 | Adjuvant (A) | 2017-08-27 | 2017-09-12 | FEC | 02 | N | CARBOPLATIN + DOCETAXEL + TRASTUZUMAB | 100457558 |
| 210003476 | 210007248 | null | null | null | null | 2020-01-07 | FEC + DOCETAXEL | null | null | FEC + DOCETAXEL | 100010778 |
| 210003700 | 210007253 | 1.69 | null | Palliative (P) | 2018-04-23 | 2018-04-29 | Everolimus 10mg | null | N | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 100539097 |
| 210003725 | 210007254 | 1.63 | 88.9 | Palliative (P) | 2017-06-17 | 2017-06-21 | CARBOPLATIN + PACLITAXEL | null | N | EVEROLIMUS | 100388097 |
| 210003779 | 210007257 | 1.7 | 73 | Neo-adjuvant (N) | 2017-10-01 | 2017-10-30 | null | null | N | TRIAL UNSPECIFIED | 101717009 |
| 210003860 | 210007260 | null | 69.55 | null | null | 2018-11-15 | FEC 100 | null | null | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 100471407 |
| 210002501 | 210007264 | 1.55 | 81.6 | Adjuvant (A) | 2018-03-11 | 2018-03-25 | Capecitabine | null | N | CARBOPLATIN + DOCETAXEL + TRASTUZUMAB | 100816955 |
| 210002154 | 210008121 | 1.65 | 124.5 | Adjuvant (A) | null | 2016-09-02 | Trastuzumab Subcutaneous | 02 | N | TRASTUZUMAB | 100827829 |
| 210002156 | 210008122 | 1.63 | 82 | Palliative (P) | null | 2017-07-31 | Docetaxel | null | null | DOCETAXEL | 100527491 |
| 210002157 | 210008123 | 1.58 | null | Adjuvant (A) | 2018-04-23 | 2018-04-30 | Trastuzumab Subcutaneous | null | N | TRASTUZUMAB | 100097238 |
| 210002162 | 210008126 | 1.62 | 100.6 | Adjuvant (A) | 2018-12-06 | 2018-12-06 | EC | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 101511780 |
| 210002163 | 210008127 | null | null | null | null | 2018-07-09 | Trastuzumab 21 day maintenance | 02 | null | TRASTUZUMAB | 100828560 |
| 210002164 | 210008128 | 1.75 | 50.4 | Adjuvant (A) | null | 2018-09-11 | Trastuzumab | null | N | TRASTUZUMAB | 101609360 |
| 210002165 | 210008129 | null | 68.2 | null | 2021-03-14 | 2021-05-22 | EC | 02 | null | CYCLOPHOSPHAMIDE + EPIRUBICIN | 101108887 |
| 210002167 | 210008130 | null | 75.45 | null | 2016-01-26 | 2017-04-08 | Docetaxel | null | null | DOCETAXEL | 100450806 |
| 210002169 | 210008132 | 1.7 | 67.9 | Adjuvant (A) | null | 2022-04-14 | PACLITAXEL | null | N | PACLITAXEL | 100533630 |
| 210002170 | 210008133 | 1.51 | 79.3 | Adjuvant (A) | 2020-06-03 | 2020-09-20 | Docetaxel | 02 | N | DOCETAXEL | 101344909 |
| 210002174 | 210008135 | null | null | null | 2017-03-31 | 2017-04-15 | EC | null | null | CYCLOPHOSPHAMIDE + EPIRUBICIN | 100944998 |
| 210002175 | 210008136 | 1.73 | 107 | Palliative (P) | 2018-07-02 | 2018-12-26 | EC | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 100388905 |
| 210002176 | 210008137 | 1.5 | 66.1 | Neo-adjuvant (N) | 2018-01-31 | 2018-04-24 | Paclitaxel 7 day | 02 | N | PACLITAXEL | 100415554 |
| 210002177 | 210008138 | 1.7 | 78.5 | Adjuvant (A) | 2016-10-10 | 2016-11-07 | Docetaxel | null | N | DOCETAXEL | 101503833 |
| 210002178 | 210008139 | 1.67 | 87.3 | Adjuvant (A) | null | 2020-08-13 | Paclitaxel 7 day | 02 | N | PACLITAXEL | 101532564 |
| 210002180 | 210008140 | 1.62 | 53.9 | Adjuvant (A) | 2017-02-19 | 2017-02-20 | Trastuzumab Subcutaneous | 02 | N | TRASTUZUMAB | 101812162 |
| 210002182 | 210008141 | 1.65 | 64.4 | Adjuvant (A) | 2019-12-24 | 2020-03-04 | Trastuzumab Subcutaneous | 02 | N | TRASTUZUMAB | 100279032 |
| 210002183 | 210008142 | 1.54 | 75.4 | Adjuvant (A) | 2018-08-23 | 2018-11-02 | EC | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 101316988 |
| 210002185 | 210008144 | 1.59 | 87 | Adjuvant (A) | null | 2017-01-05 | Trastuzumab Subcutaneous | null | N | TRASTUZUMAB | 101288944 |
| 210002186 | 210008145 | 1.68 | 93.6 | Adjuvant (A) | 2018-07-15 | 2019-05-16 | EC | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 101496677 |
| 210002187 | 210008146 | 1.63 | 86.2 | Palliative (P) | null | 2017-04-01 | Docetaxel | 02 | N | DOCETAXEL | 100468124 |
| 210002190 | 210008148 | 1.58 | 83.4 | Adjuvant (A) | 2019-03-10 | 2020-05-16 | Trastuzumab Subcutaneous | null | N | TRASTUZUMAB | 101413304 |
| 210002192 | 210008149 | 1.48 | 74.9 | Adjuvant (A) | null | 2017-11-13 | Trastuzumab | 02 | N | TRASTUZUMAB | 101479248 |
| 210002194 | 210008150 | 1.65 | 82.5 | Adjuvant (A) | null | 2020-01-23 | Trastuzumab Subcutaneous | 02 | N | TRASTUZUMAB | 100630436 |
| 210002195 | 210008151 | 1.63 | 70 | Palliative (P) | 2018-11-13 | 2018-11-14 | Paclitaxel 7 day | 02 | N | PACLITAXEL | 100663655 |
| 210002196 | 210008152 | 1.63 | null | Palliative (P) | 2022-01-31 | 2022-04-02 | PACLITAXEL | 02 | N | PACLITAXEL | 100425088 |
| 210002197 | 210008153 | 1.63 | 70 | Adjuvant (A) | 2020-05-19 | 2020-08-05 | Trastuzumab Subcutaneous | null | N | TRASTUZUMAB | 101166836 |
| 210002199 | 210008155 | null | 74.8 | null | null | 2018-11-18 | EC | 02 | null | CYCLOPHOSPHAMIDE + EPIRUBICIN | 100074046 |
| 210002200 | 210008156 | 1.7 | 74.3 | null | 2021-05-31 | 2021-08-29 | PACLITAXEL | null | null | PACLITAXEL | 100503882 |
| 210002202 | 210008157 | 1.58 | 83.4 | Neo-adjuvant (N) | null | 2022-02-07 | Trastuzumab Subcutaneous | null | N | TRASTUZUMAB | 100559154 |